

# Fatty liver disease: Understanding the epidemic and exploring novel therapeutic approaches.

Miranda Hoekstra\*

Department of Systems Pharmacology and Pharmacy, Leiden University, Leiden, the Netherlands

## Introduction

Fatty Liver Disease (FLD), a condition characterized by the accumulation of excess fat in the liver cells, has emerged as a silent epidemic worldwide. Formerly associated primarily with alcohol consumption, non-alcoholic fatty liver disease (NAFLD) has gained prominence in recent years due to the global surge in obesity and metabolic syndrome. FLD has become a pervasive health issue, affecting millions of individuals across the globe. The World Gastroenterology Organization estimates that approximately 25% of the global population is grappling with NAFLD. This condition spans a spectrum, ranging from simple fatty liver to the more severe non-alcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and, in extreme cases, liver failure [1, 2].

The primary driver behind the surge in FLD is the obesity epidemic. Excessive caloric intake, coupled with sedentary lifestyles, has led to an unprecedented rise in obesity rates. The liver, crucial for metabolic functions, is adversely impacted by this surge in adiposity. High levels of visceral fat contribute to insulin resistance, prompting the liver to store fat instead of metabolizing it effectively. Beyond obesity, genetic factors, insulin resistance, and certain metabolic conditions play a role in the development of FLD. Additionally, dietary choices, particularly the consumption of high-fructose corn syrup and saturated fats, contribute to the accumulation of fat in the liver. These multifaceted causes highlight the complexity of FLD and underscore the need for comprehensive approaches in both prevention and treatment [3, 4].

Current strategies for managing FLD primarily revolve around lifestyle modifications, including dietary changes and increased physical activity. While these interventions can be effective, the challenge lies in sustaining long-term adherence. Moreover, there is a lack of specific pharmacological interventions for FLD, especially for the more advanced stages such as NASH. Recognizing the limitations of conventional treatments, researchers are exploring novel therapeutic approaches to combat FLD. One promising avenue involves the use of pharmacological agents that target specific pathways involved in lipid metabolism and inflammation within the liver [5, 6].

One such emerging field is the investigation of peroxisome proliferator-activated receptors (PPARs) agonists. PPARs are nuclear receptors that regulate genes involved in lipid metabolism

and inflammation. Certain drugs that activate PPARs show promise in improving insulin sensitivity, reducing hepatic fat accumulation, and alleviating inflammation in the liver [7, 8].

Another area of research is the exploration of antifibrotic agents. As FLD progresses, fibrosis can occur in the liver, leading to the development of cirrhosis. Antifibrotic drugs aim to inhibit or reverse this process, preventing the escalation of FLD to more severe stages. Furthermore, ongoing research into gut microbiota modulation is shedding light on the intricate relationship between the gut and liver health. Probiotics and prebiotics are being investigated for their potential to restore gut microbial balance, reducing inflammation in the liver and mitigating FLD progression [9, 10].

## Conclusion

Fatty Liver Disease has evolved from a relatively obscure condition to a global health epidemic, with the rise of obesity and metabolic syndrome playing a pivotal role in its prevalence. While lifestyle modifications remain fundamental in managing FLD, the exploration of novel therapeutic approaches offers hope for more targeted and effective treatments. The ongoing research into PPAR agonists, antifibrotic agents, and gut microbiota modulation presents a promising frontier in the battle against FLD, offering prospects for improved outcomes and a brighter future for those affected by this silent but pervasive health crisis.

## References

1. Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors. *Clin Gastroenterol Hepatol.* 2023;21(2):406-14.
2. Sasaki T, Abe Y, Takayama M, et al. Association among extracellular superoxide dismutase genotype, plasma concentration, and comorbidity in the very old and centenarians. *Sci Rep.* 2021;11(1):8539.
3. Tian Z, Yao N, Wu Y, et al. Association between plasma level of superoxide dismutase and survival of patients with acute-on-chronic liver failure. *BMC Gastroenterol.* 2022;22(1):1-0.
4. Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, et al. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. *Diabetes Metab Res Rev.* 2022;38(3):e3502.

\*Correspondence to: Miranda Hoekstra, Department of Systems Pharmacology and Pharmacy, Leiden University, Leiden, The Netherlands, E-mail: hoekstra@gmail.com

Received: 13-Oct-2023, Manuscript No. JGDD-23-120820; Editor assigned: 16-Oct-2023, Pre QC No. JGDD-23-120820 (PQ); Reviewed: 31-Oct-2023, QC No. JGDD-23-120820; Revised: 03-Nov-2023, Manuscript No. JGDD-23-120820 (R); Published: 09-Nov-2023, DOI: 10.35841/jgdd-8.6.176

5. Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP Rep.* 2020;2(6):100192.
6. Pedersen HD, Galsgaard ED, Christoffersen BØ, et al. NASH-inducing diets in Göttingen minipigs. *J Clin Exp Gastroenterol.* 2020;10(3):211-21.
7. Sun W, Liu P, Yang B, et al. A network pharmacology approach: Inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats. *Phytomed.* 2021;88:153498.
8. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD prevalence: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2022;20(12):2809-17.
9. Tam FI, Chocholi I, Hellerhoff I, et al. Liver and vitamin B12 parameters in patients with anorexia nervosa before and after short-term weight restoration. *Psychiatry Res.* 2022;314:114673.
10. Jothimani D, Danielraj S, Narasimhan G, et al. Nonalcoholic steatohepatitis: A rapidly increasing indication for liver transplantation in India. *J Clin Exp Gastroenterol.* 2022;12(3):908-16.